Skip to main content

Silence Therapeutics plc

SLN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001479615

No open-market purchases or sales by Silence Therapeutics plc insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $253.5M in total; no superinvestor holds it.

Other share classesSLNCF

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +16 vs. previous quarter
72
13F valueReported value at the end of Q2 2026
$253.5M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding SLN, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding SLN at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Silence Therapeutics plc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 13, 2026 (view filing)10:07 AM ETAug 103 daysLateGriffiths Richard Ian10% OwnerSSale+16.5M–––4.80M afterDerivative11 lots
Jul 7, 2026 (view filing)9:09 AM ETJun 29-Jul 68 daysLateGriffiths Richard Ian10% OwnerSSale+4.63M–––10.3M afterDerivative6 lots
Feb 13, 2026 (view filing)Aug 3-Oct 27, 2025194 daysLateGriffiths Richard Ian10% OwnerSSale+66.0K–––11.8M afterDerivative2 lots
Feb 13, 2026 (view filing)Aug 3-Oct 27, 2025194 daysLateGriffiths Richard Ian10% OwnerPPurchase+66.0K–––11.8M afterDerivative2 lots
Aug 4, 2025 (view filing)Jul 31-Aug 14 daysGriffiths Richard Ian10% OwnerPPurchase+55.1K–––11.8M afterDerivative2 lots
Jul 31, 2025 (view filing)Jul 29-302 daysGriffiths Richard Ian10% OwnerPPurchase+70.4K–––11.8M afterDerivative2 lots
Jul 23, 2025 (view filing)Jul 21-222 daysGriffiths Richard Ian10% OwnerPPurchase+76.0K–––11.8M afterDerivative2 lots
Jul 16, 2025 (view filing)Jul 115 daysLateGriffiths Richard Ian10% OwnerPPurchase+84.0K–––11.7M afterDerivative
Jul 16, 2025 (view filing)Jul 151 dayGriffiths Richard Ian10% OwnerPPurchase+129.9K–––11.8M afterDerivative
Jul 10, 2025 (view filing)Jul 7-93 daysLateGriffiths Richard Ian10% OwnerPPurchase+187.4K–––11.7M afterDerivative3 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Silence Therapeutics plc at the end of Q2 2026; share changes are against Q1 2026.

See all 72 holders
Institutions holding SLN in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Siren, L.L.C.3,311,438$36.4M0.74%+400,000+13.7%Added
TCG Crossover Management, LLC3,033,560$33.3M0.80%00.0%Unchanged
Nantahala Capital Management, LLC2,693,462$29.6M0.90%+546,731+25.5%Added
Redmile Group, LLC2,164,777$23.8M1.60%00.0%Unchanged
Citadel Advisors LLC1,329,625$14.6M0.01%+94,818+7.7%Added
Nextech Invest, Ltd.952,400$10.5M0.50%00.0%Unchanged
Millennium Management LLC909,279$9.98M0.01%−164,912−15.4%Reduced
Polygon Management Ltd.764,256$8.39M1.37%+134,095+21.3%Added
Soleus Capital Management, L.P.630,000$6.92M0.24%+630,000New
Balyasny Asset Management LLC610,980$6.71M0.01%+610,980New